Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-03-27

Clinical Trial Update: Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL) [Phase 2]

View source ↗

Summary

Phase 2 trial update investigating lenalidomide as an immune adjuvant in patients with chronic lymphocytic leukemia (CLL); trial status terminated with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Lenalidomide (lenalidomide)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Hematologic Disorder | Phase 2 | Status: TERMINATED | Results posted: 2018-03-27